Elsevier

The Lancet

Volume 343, Issue 8912, 18 June 1994, Pages 1554-1555
The Lancet

Viewpoint
Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin

https://doi.org/10.1016/S0140-6736(94)92945-9Get rights and content

References (18)

  • Mjtm Mol et al.

    Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia

    Lancet

    (1986)
  • Dr Illingworth et al.

    Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia.

    Atherosclerosis

    (1992)
  • Anatomical therapeutic chemical classification index

    (1994)
  • Rh Bradford et al.

    Expanded clinical evaluation of lovastatin (EXCEL) study results

    Arch Intern Med

    (1991)
  • Hy Pan et al.

    Comparative efficacy of once daily versus twice daily pravastatin in primary hypercholesterolaemia

    Clin Ther

    (1991)
  • Dr Illingworth et al.

    Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia

    J Clin Invest

    (1984)
  • Rj Havel et al.

    Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multi-center study

    Ann Intern Med

    (1987)
  • O. Wiklund et al.

    Treatment of familial hypercholesterolemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels

    J Intern Med

    (1990)
There are more references available in the full text version of this article.

Cited by (80)

  • Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3β phosphorylation

    2016, Biochemical and Biophysical Research Communications
    Citation Excerpt :

    Statins are the most effective drugs in lowering plasma cholesterol and prevention of cardiovascular disease [1].

  • Simvastatin inhibits glucose uptake activity and GLUT4 translocation through suppression of the IR/IRS-1/Akt signaling in C2C12 myotubes

    2016, Biomedicine and Pharmacotherapy
    Citation Excerpt :

    These findings suggest that the impairment of GLUT4 translocation induced by simavstain may be associated with decrease in Rac1-GTP activity. Statins are inhibitors of hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase, which can inhibit the synthesis of endogenouse cholesterol [1]. It has been demonstrated that statins are associated with the risk of new-onset diabetes in long-term therapy [2,6], but the underlying mechanism remains perplexing.

  • Expression of an endothelial-type nitric oxide synthase isoform in human neutrophils: Modification by tumor necrosis factor-alpha and during acute myocardial infarction

    2001, Journal of the American College of Cardiology
    Citation Excerpt :

    This was accompanied by an increased expression of eNOS protein, suggesting an association between the binding of cytosolic proteins to the 3′-UTR of eNOS mRNA and the decrease in eNOS protein expression. The levels of simvastatin that prevented eNOS protein expression in TNF-alpha–stimulated neutrophils are within the range of the expected tissue levels obtained with recommended doses (33). It is noteworthy that the binding region of the neutrophil cytosolic proteins flanks a potential stem-loop structure in the 3′-UTR of eNOS mRNA.

  • Hmg-coa reductase inhibitors

    2001, Advances in Protein Chemistry
View all citing articles on Scopus
View full text